News – Page 974 – Endpoints News

Philippines DOJ preps criminal charges for Sanofi, health officials involved in the Dengvaxia mess

7 years ago

After thyroid eye drug scores in PhIII test, Horizon Pharma readies marketing application

7 years ago

Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz

7 years ago

Eager to think bigger than China, Ascletis woos top Merck exec to run R&D

7 years ago

Kaleido prices $75M IPO well below range; Sage raises $575M ahead of FDA decision

7 years ago

Another PhIII RSV failure thumps beleaguered Novavax, but execs claim there's a way forward

7 years ago

Robotic pill tech found to be safe, tolerable in early human study, paving ground for oral biologics

7 years ago

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

7 years ago

Looking to capitalize on genetic modifiers, Maze Therapeutics launches with $191M in financing led by Arch, Third ...

7 years ago

Ahead of key NASH readout, France's Genfit readies plans for $100M US IPO

7 years ago

Gottlieb testifies on status of FDA operations after government shutdown

7 years ago

Investor opposition to Bristol-Myers' $74B Celgene buyout grows as activist Starboard joins the rebellion

7 years ago

Michael Cohen on Novartis ties: '(T)hey wanted me to provide access to government, including the president'

7 years ago

China's CStone raises $285M in IPO; Axial raises $25M for microbiome work on Parkinson's, autism

7 years ago

Scientists hold out hope for regenerative infusion via brain implant — despite failing its first test in ...

7 years ago

Plotting to go toe-to-toe with heavyweight Pfizer, little Eidos plans quick score in PhIII ATTR-CM study

7 years ago

Sarepta posts early, rosy gene therapy data for limb girdle muscular dystrophy — fueling $165M buyout of partner

7 years ago

Novartis, AbbVie dominate the top 10 list of blockbusters prepping for a 2019 marketing launch

7 years ago

FDA hands back Adamis' application for an ED drug, looking for more data

7 years ago

Parexel recruits top FDA oncology expert Amy McKee for new R&D initiative

7 years ago

Blackstone antes $250M on its first big biotech bet, focused on a cardio drug spun out of Novartis

7 years ago

FDA experts turn thumbs down on Karyopharm’s troubled pitch for an accelerated OK — but not all of them

7 years ago

In landmark hearing, drugmakers and lawmakers agree that US policy on drug pricing is ripe for change — but there's ...

7 years ago

Amicus blueprints growth plans for Philly-based gene therapy group; Cash-strapped Compugen restructures, cuts 35 ...

7 years ago

First page Previous page 971 972 973974975 976 977 Next page Last page